Daniel Offen
23Patents
5h-index
21Co-inventors
69Inventor score
Filing activity: Jun 1, 1999 → Jul 5, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6369106B1 | Treatment of ischemic brain injuries with brain targeted anti oxidant compounds | Chemistry; Metallurgy | 33 | Expired |
| US6420429B1 | Brain targeted low molecular weight hydrophobic antioxidant compounds | Human Necessities | 18 | Expired |
| US8663987B2 | Mesenchymal stem cells for the treatment of CNS diseases | Chemistry; Metallurgy | 7 | Active |
| US8900574B2 | Mesenchymal stem cells for the treatment of CNS diseases | Chemistry; Metallurgy | 5 | Active |
| US8647874B2 | Isolated cells and populations comprising same for the treatment of CNS diseases | Chemistry; Metallurgy | 5 | Active |
| US9474787B2 | Mesenchymal stem cells for the treatment of CNS diseases | Chemistry; Metallurgy | 4 | Active |
| US9717761B2 | Stem cell-derived neural cells for cell therapy in neurological disorders | Chemistry; Metallurgy | 1 | Active |
| US10052363B2 | Mesenchymal stem cells for the treatment of CNS diseases | Chemistry; Metallurgy | 1 | Active |
| US11129852B2 | Mesenchymal cell-derived exosomes to treat neurological disorders | Human Necessities | 0 | Active |
| US10040836B2 | Peptides for the treatment of neurodegenerative diseases | Chemistry; Metallurgy | 0 | Active |
| US10723706B2 | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | Human Necessities | 0 | Active |
| US11648260B2 | Vesicles comprising a PTEN inhibitor and uses of same | Chemistry; Metallurgy | 0 | Active |
| US10220077B2 | Combination treatment for amyotrophic lateral sclerosis (ALS) | Chemistry; Metallurgy | 0 | Active |
| US8378070B2 | Peptides for the regulation of neurotransmitter sequestration and release | Chemistry; Metallurgy | 0 | Active |
| US9879225B2 | Isolated cells and populations comprising same for the treatment of CNS diseases | Chemistry; Metallurgy | 0 | Active |
| US9023800B2 | Peptides for the treatment of oxidative stress related disorders | Human Necessities | 0 | Active |
| US11185572B2 | Mesenchymal stem cells for the treatment of CNS diseases | Chemistry; Metallurgy | 0 | Active |
| US8212001B2 | Peptides for the treatment of oxidative stress related disorders | Human Necessities | 0 | Active |
| US9598478B2 | Peptides for the treatment of neurodegenerative diseases | Chemistry; Metallurgy | 0 | Active |
| US11104651B2 | PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins | Human Necessities | 0 | Active |
| US10744162B2 | Genetically modified muscle cells which express neurotrophic factors | Chemistry; Metallurgy | 0 | Active |
| US9365828B2 | Genetically modified muscle cells which express neurotrophic factors | Chemistry; Metallurgy | 0 | Active |
| US10869899B2 | Isolated cells and populations comprising same for the treatment of CNS diseases | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.